In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient’s own immune cells to fight cancer. “Cancer often gains the upper hand by suppressing the immune system. Our approach flips the scrip...
Category: Scientific
-
October 30, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
-
October 24, 2024
Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as a “Next Big Thing” in Cancer Immunotherapy
Dr. Borriello was a featured speaker at a live webinar entitled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as the ‘Next Big Thing’ in Cancer Immunotherapy”. The live webinar, moderated by Lumanity, brought together a diver...
-
October 13, 2024
Alloplex’s Groundbreaking Cancer Immunotherapy Selected for SITC24 ‘Top 100’ Presentation
Alloplex Biotherapeutics is pleased to announce that our innovative SUPLEXA immunotherapy platform has been recognized by the Society for Immunotherapy of Cancer (SITC) for its upcoming international conference in Houston, Tx, this November. Two abstracts featuring SUPLEXA have been accepted for pos...
-
September 30, 2024
Dr. Borriello to present at live webinar on Immuno-Oncology R&D Challenges
Dr. Borriello will be a featured speaker at an upcoming live webinar entitled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as the ‘Next Big Thing’ in Cancer Immunotherapy”. The live webinar, being moderated by Lumanity,...
-
September 27, 2024
Advancing Cellular Therapies: Alloplex’s SUPLEXA Platform Poised to Address Solid Tumor Challenges
In a recent interview with Immuno-Oncology Insights, Dr. Frank Borriello, CEO of Alloplex Biotherapeutics, discussed the potential of Alloplex’s SUPLEXA platform—a novel, autologous, non-engineered cellular therapy designed to treat solid tumors. Solid tumors have remained a significant challeng...
-
June 12, 2024
SITC23 Posters with Oral Presentation recording by Alloplex Biotherapeutics Inc’s Founder and Chief Executive Officer, Dr. Frank Borriello.
SITC 2023 Poster 381 and 727 with Audio Commentary by Dr. Borriello
-
March 27, 2024
Alloplex set to validate crucial immunotherapy hypothesis and expands corporate structure with advisory panel.
Alloplex Biotherapeutics has identified cancer tumor types responsive to its lead technology platform, SUPLEXA, in a single-agent study.
-
January 10, 2024
Naturally Occurring Immune Cells may push through where CAR T cells fall short, reports Genetic Engineering and Biotechnology News
Genetic Engineering & Biotechnology News recently published a feature story entitled ‘Immune Cell Therapy May Become More Naturalistic'.
-
September 7, 2023
Two abstracts on Alloplex’s lead technology platform, SUPLEXA, accepted for presentation at SITC23
Dr. Rohit Joshi of CRSA and Alloplex's leadership team will present the latest developments and data from SUPLEXA-101 phase 1 in-human trials in San Diego, CA (November 1 - 5, 2023)
The Society for Immunotherapy of Cancer has accepted two abstracts in relation to the trial of Alloplex’s lead technology platform, SUPLEXA, for presentation at this year’s 38th annual SITC meeting and conference. The posters to be presented by Dr. Rohit Joshi, alongside the Alloplex lea...
-
July 25, 2023
Dr. Borriello to present at CHI immuno-oncology summit 2023 in Boston
Dr. Frank Borriello, Alloplex Biotherapeutics Inc’s Founder and CEO, will be speaking at CHI’s 11th Annual Immuno-Ongolocy Summit #IOSummit and chairing the Emerging Cell-Based Therapies session at the Seaport Hotel, Boston, M.A. on August 9. The session starts at 8.55 am and Dr. Borriello’s p...
-
June 14, 2023
Alloplex will participate in the CHI’s 7th Annual Immuno-Oncology Summit Europe
Alloplex Biotherapeutics’ Founder and CEO, Dr. Frank Borriello, is a speaker within the Gamma Delta Immunotherapy ‘Exploiting and Enhancing Unique Properties for Cancer Treatment’ track of the CHI Immuno-Oncology Summit Europe, taking place in London from June 20 to 22, 2023. His presentation,...
-
July 27, 2022
Dr. Frank Borriello to speak at Gamma Delta T Therapies Summit.
July 28, 2022 in Boston.
Alloplex’s Founder and CEO, Dr. Frank Borriello, will be speaking at the 3rd Gamma Delta T Therapies Summit on Thursday 28th July 2022 at 11am in a session titled “Reviewing the clinical safety and efficacy of gamma delta therapies” on the Response in Solid Tumors of Non-Engineered Autologous...
-
April 11, 2022
Alloplex SUPLEXA cells resist immunosuppressive action of two inhibitory cytokines typically found in tumor microenvironment
On April 12, 2022, Jim Lederer, MD, Chief Scientific Officer of Alloplex Biotherapeutics Inc. will present a Poster at the AACR 2022 Annual Meeting in New Orleans, Louisiana: AACR Abstract: IL-10/TGFβ Abstract Control Number: 3599 Title: Interleukin-10 and transforming growth factor-beta do not sup...
-
March 29, 2022
Alloplex appoints CLL expert Dr. Jennifer Brown to its scientific advisory board
Dr. Brown, the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts, is internationally known fo...
-
December 8, 2021
Alloplex appoints Dr. Andre Goy to its scientific advisory board
Dr. Goy is Physician in Chief of Hackensack Meridian Health Oncology Care Transformation Service; Chairman & Chief Physician Officer of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma; Academic Chairman Oncology at Hackensack Meridian School...
-
November 15, 2021
Alloplex presents poster describing novel tumor-killing cells at SITC 2021 Conference
Non-engineered SUPLEXA cells demonstrate potent activity against patient-derived cancer organoids in vitro.
Today Alloplex Biotherapeutics released details of its abstract entitled Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells presented at SITC 2021. Alloplex’s abstract shows that the organization can generate tumor-killing cells from PBMCs using a clinical grade manufact...
-
May 1, 2020
Alloplex Biotherapeutics Announces Addition to its Scientific Advisory Board
Alloplex Biotherapeutics is pleased to announce the addition of Dr. Robin Robinson to our scientific advisory board.